行情

LCTX

LCTX

Lineage Cell The
AMEX
1.420
-0.050
-3.40%
盘后: 1.439 +0.019 +1.33% 16:03 11/25 EST
开盘
1.470
昨收
1.470
最高
1.470
最低
1.400
成交量
15.06万
成交额
0
52周最高
2.710
52周最低
1.020
市值
2.41亿
市盈率(TTM)
-4.9084
分时
5日
1月
3月
1年
5年
-- 收益快讯 (LCTX) LINEAGE CELL THERAPEUTICS 报告第三季度收入 300 万美元
-- 收益快讯 (LCTX) LINEAGE CELL THERAPEUTICS 报告第三季度收入 300 万美元
MT Newswires · 11/10 16:08
--Baird 以 5 美元的价格目标以优于大盘的价格启动 Lineage Cell Therapeutics
--Baird 以 5 美元的价格目标以优于大盘的价格启动 Lineage Cell Therapeutics
MT Newswires · 11/02 07:11
Lineage Cell Therapeutics 任命 Jill Howe 为财务主管
Lineage Cell Therapeutics 任命 Jill Howe 为财务主管
MT Newswires · 10/31 11:36
Lineage Cell Therapeutics 收到美国专利许可通知
Lineage Cell Therapeutics 收到美国专利许可通知
MT Newswires · 10/10 09:56
Lineage Cell Therapeutics 在加利福尼亚开设了新的研究单位,并在以色列扩大了制造设施
Lineage Cell Therapeutics 在加利福尼亚开设了新的研究单位,并在以色列扩大了制造设施
MT Newswires · 10/03 11:38
LCTX 简况
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cell therapies to address unmet medical needs. The Company designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. It has three allogeneic product candidates: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA). OPC1 is an oligodendrocyte progenitor cell therapy, which is in a follow-up for a Phase I/IIa multicenter clinical trial for spinal cord injuries (SCI). VAC is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells. Its VAC product candidates include, VAC2, which is in a Phase I clinical trial in non-small cell lung cancer (NSCLC).

微牛提供Lineage Cell Therapeutics Inc(AMEX-LCTX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的LCTX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易LCTX股票基本功能。